Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGT-NeoBoost T-cells
- Development stage
- Preclinical
- Lead developer
- AngenMed
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AGT-NeoBoost T-cells (NeoBoost® T-cells) is a personalized, neoantigen-specific autologous T-cell therapy developed by AngenMed Therapeutics. As a component of the ANG-NeoSync® platform, the therapy is produced by first identifying patient-specific tumor neoantigens through whole-genome sequencing. These neoantigens are used to create an mRNA vaccine that primes autologous dendritic cells (AGT-NeoPrime® DC). These primed dendritic cells are then co-cultured with the patient's T cells ex vivo, leading to a greater than 100-fold expansion of neoantigen-specific T cells. The final product, NeoBoost® T-cells, is re-infused into the patient to recognize and eliminate cancer cells expressing the targeted neoantigens. The therapy is currently in development for the treatment of various solid tumors.
- Brand names
- NeoBoost T-cellsNeoBoost® T-cells
- Other names
- NeoBoost
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on AGT-NeoBoost T-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGT-NeoBoost T-cells.